



## *The Medical* **Bulletin**

### Drug Corner

#### Use of SGLT 2 Inhibitors in Hyperuricemia

- Xanthine oxidase inhibitors (allopurinol and oxypurinol) have had little benefit and may exert detrimental effects in patients with chronic heart failure in randomized controlled trials.
- More selective and potent inhibitor febuxostat increases the risk of cardiovascular death more than allopurinol death by virtue of an action to mute the beneficial effects of nitric oxide.
- Drugs that act to mitigate oxidative stress in the failing heart (e.g., SGLT2 inhibitors) may lead simultaneously to lowering of uric acid and cardio protection.
- A recent meta-analysis of 62 studies, comprising 34941 patients shows that any of the SGLT2 inhibitors significantly decreased serum uric acid levels compared to control. It suggests that SGLT2i might be beneficial for diabetic patients with hyperuricemia.

*Dr. N. K. Singh,  
MD, FICP, Diabetologist physician, Dhanbad*